Viridian Therapeutics Reports Q2 2026 Revenue Increase to $284,000, Net Loss of $127.1 Million

Viridian Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $284,000, a significant increase from $75,000 in the same period last year. The revenue primarily stemmed from a collaboration agreement with Kissei Pharmaceutical, which contributed $233,000 in license revenue. Despite this uptick in revenue, the company recorded a net loss of $127.1 million for the quarter, compared to a loss of $100.7 million in the prior year, reflecting an increase in operating expenses driven by heightened selling, general, and administrative costs associated with the launch of its newly approved product, veligrotug.

In terms of operational changes, Viridian's total operating expenses rose to $126.6 million in the second quarter, up from $106.8 million a year earlier. This increase was largely attributed to a $34.8 million rise in selling, general, and administrative expenses, which were necessary to support the commercial launch of veligrotug, approved by the FDA in June 2026 for the treatment of thyroid eye disease (TED). Research and development expenses decreased to $71.6 million from $86.6 million, primarily due to reduced clinical trial costs associated with the timing of ongoing studies.

The company’s balance sheet as of June 30, 2026, showed total assets of $1.1 billion, up from $899.4 million at the end of 2025. Cash and cash equivalents decreased to $165 million from $212.4 million, while marketable securities increased to $816.5 million from $662.3 million. The company’s liabilities also rose significantly, totaling $435.1 million, compared to $177.3 million at the end of the previous year, largely due to the issuance of $250 million in convertible notes in May 2026 and the establishment of a liability related to the sale of future revenue.

Viridian's strategic focus remains on the commercialization of veligrotug and the development of its second product candidate, elegrobart, which is currently in pivotal clinical trials. The company anticipates submitting a Biologics License Application (BLA) for elegrobart in the first quarter of 2027. Additionally, Viridian is expanding its pipeline with engineered FcRn inhibitors and a TSHR inhibitor program, which are expected to address a range of autoimmune diseases. The company maintains a strong liquidity position, with $981.5 million in cash, cash equivalents, and marketable securities, which it believes will support its operations for at least the next twelve months.